- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07632222
High-Protein Diet for Improving Alcoholic Fatty Liver Disease (HP-AFLD-RCT)
Efficacy and Safety of a High-Protein Diet Versus a Standard Diet in Patients With Alcoholic Fatty Liver Disease: A Randomized Controlled Trial
Alcohol-associated liver disease (ALD) is a major cause of mortality from malignant liver diseases, accounting for 47.9% of cirrhosis-related deaths and 30% of liver cancer-related deaths annually. In China, both alcohol consumption and the prevalence of ALD (approximately 5.15%) are on the rise, making ALD an increasingly significant health concern for the population. Alcohol-associated fatty liver disease (AFLD), as the initial and most reversible stage of ALD, is primarily characterized by excessive hepatic lipid deposition, mild liver injury accompanied by mild inflammation. It can progressively develop into alcoholic hepatitis, and in some patients, advance to liver fibrosis, cirrhosis, and even hepatocellular carcinoma. Currently, there is a lack of effective clinical treatments for AFLD. Although alcohol abstinence remains the optimal choice for reversing AFLD, it is often difficult for individuals with alcohol dependence to maintain.
A high-protein diet generally refers to a dietary pattern where protein accounts for more than 20% of total energy intake. A protein contribution of 30% is a common ratio in research investigating high-protein dietary interventions for metabolic diseases. Population-based intervention studies have demonstrated that a high-protein diet at this ratio significantly reduces hepatic fat content. For instance, a study published in Gastroenterology (2017) reported that a 6-week isocaloric high-protein diet (macronutrient distribution: 30% protein, 40% carbohydrates, 30% fat) significantly improved hepatic lipid deposition in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM). Research in Diabetologia (2019) showed that a 6-week isocaloric high-protein diet (30% protein, 30% carbohydrates, 40% fat) significantly reduced hepatic fat content in patients with T2DM. Additionally, a study in Liver International (2020) indicated that a 3-week energy-restricted high-protein diet (30% protein, 35%-45% carbohydrates, 25%-30% fat) significantly decreased hepatic fat content in NAFLD patients. Importantly, none of the aforementioned studies reported adverse events associated with the high-protein dietary interventions. Furthermore, a population-based intervention study published in Annals of Internal Medicine revealed that a low-carbohydrate, high-fat diet was more effective than a high-carbohydrate, low-fat diet in reducing hepatic fat content over a 6-month period in patients with NAFLD and T2DM. These findings suggest that increasing the percentage of energy from protein by reducing carbohydrate intake may yield superior improvements. Based on the macronutrient distributions from the referenced population interventions, and considering that a 30% fat energy contribution closely aligns with the typical dietary fat intake of the Chinese AFLD population, we established the macronutrient distribution for the high-protein diet group as 30% protein, 40% carbohydrates, and 30% fat.
This study intends to conduct a randomized controlled trial to investigate the effects of increasing the percentage of energy from protein under an isocaloric dietary pattern on liver function, hepatic fat content, and glucose-lipid metabolism in individuals with AFLD. The aim is to elucidate the mechanisms underlying its beneficial effects on AFLD, thereby providing population-based evidence and strategies for health promotion in this patient group.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Contato de estudo
- Nome: Qingling Huang, Dr.
- Número de telefone: +8615267148306
- E-mail: hqingling0306@163.com
Estude backup de contato
- Nome: Kaixin Pan
- Número de telefone: +8613568620076
- E-mail: 18966486859@163.com
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Aged between 30 and 65 years old.
- Able to understand the study and voluntarily sign the informed consent form.
- Meet the clinical diagnostic criteria for alcohol-associated fatty liver disease (AFLD): a history of alcohol consumption for ≥5 years, with an average daily ethanol intake of ≥20 g/d; clinically diagnosed with fatty liver (indicated by abdominal ultrasound or a liver MRI proton density fat fraction [MRI-PDFF] ≥5.2%).
Exclusion Criteria:
- Average daily ethanol intake >80 g/d.
- Presence of other hepatobiliary diseases, such as autoimmune liver disease, viral hepatitis, liver fibrosis, or cirrhosis.
- Presence of severe cardiovascular or cerebrovascular diseases, or renal insufficiency.
- Patients with tumors or other severe systemic diseases.
- Patients with gastrointestinal disorders, or those with known protein allergy or intolerance.
- Long-term use of medications known to cause hepatic steatosis or steatohepatitis (e.g., amiodarone or tamoxifen), nutritional supplements, or probiotics.
- Total daily energy intake (excluding energy from alcohol) <1900 kcal or ≥2900 kcal.
- Participation in another interventional study within the past year, or scheduled to receive non-study treatments during the trial period.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: high protein diet group
Arm Description: High-protein meals will be provided for 5 days per week, and high-protein recipes will be provided for the two weekend days.
|
high protein diet
|
|
Comparador de Placebo: control diet group
Control meals will be provided for 5 days per week, and control recipes will be provided for the two weekend days.
|
control diet
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Magnetic Resonance Imaging proton density fat fraction in hepatic steatosis
Prazo: Baseline, up to 60 days of the study
|
Magnetic Resonance Imaging (MRI) technology utilizes magnetic fields and radiofrequency pulses to conduct non-invasive examinations of tissues.
When measuring liver fat content, MRI employs water-fat separation techniques to quantify the proton density of water molecules and fat molecules (PDFF) within the liver, thereby providing a quantitative analysis of fat content.
|
Baseline, up to 60 days of the study
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Liver function
Prazo: Baseline, up to 60 days of the study
|
Alanine aminotransferase (ALT, U/L), aspartate aminotransferase (AST, U/L), γ-glutamyltransferase (γ-GT, U/L), alkaline phosphatase (ALP, U/L), total bilirubin (TBIL, μmol/L), direct bilirubin (DBIL, μmol/L), indirect bilirubin (IBIL, μmol/L), alcohol dehydrogenase (ADH, U/L), aldehyde dehydrogenase (ALDH, U/L).
|
Baseline, up to 60 days of the study
|
|
Glucose metabolism
Prazo: Baseline, up to 60 days of the study
|
Hemoglobin A1c (HbA1c, %), Fasting blood glucose (FBG, mmol/L)
|
Baseline, up to 60 days of the study
|
|
Lipid metabolism
Prazo: Baseline, up to 60 days of the study
|
Serum triglycerides (TG, mmol/L), total cholesterol (TC, mmol/L), low-density lipoprotein cholesterol (LDL-C, mmol/L), high-density lipoprotein cholesterol (HDL-C, mmol/L), apolipoprotein A-I (ApoA-I, g/L), apolipoprotein B (Apo B, g/L).
|
Baseline, up to 60 days of the study
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Inflammation level
Prazo: Baseline, up to 60 days of the study
|
High-sensitivity C-reactive protein (hs-CRP, mg/L), tumor necrosis factor (TNF-α, pg/mL), interleukins (IL-1β, pg/mL), interleukins (IL-6, pg/mL).
|
Baseline, up to 60 days of the study
|
|
Kidney function
Prazo: Baseline, up to 60 days of the study
|
Blood creatinine (CREA, μmol/L), urea nitrogen (BUN, mmol/L), uric acid (UA, μmol/L).
|
Baseline, up to 60 days of the study
|
|
Intestinal flora
Prazo: Baseline, up to 60 days of the study
|
16s rRNA sequencing
|
Baseline, up to 60 days of the study
|
|
serum untargeted metabolomics
Prazo: Baseline, up to 60 days of the study
|
serum untargeted metabolomics
|
Baseline, up to 60 days of the study
|
|
biomarkers of oxidative stress
Prazo: Baseline, up to 60 days of the study
|
Urinary 8-isoprostane(pg/mL)
|
Baseline, up to 60 days of the study
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Cadeira de estudo: Songtao Li, Zhejiang Chinese Medical University
Publicações e links úteis
Publicações Gerais
- Marin-Alejandre BA, Abete I, Cantero I, Monreal JI, Elorz M, Herrero JI, Benito-Boillos A, Quiroga J, Martinez-Echeverria A, Uriz-Otano JI, Huarte-Muniesa MP, Tur JA, Martinez JA, Zulet MA. The Metabolic and Hepatic Impact of Two Personalized Dietary Strategies in Subjects with Obesity and Nonalcoholic Fatty Liver Disease: The Fatty Liver in Obesity (FLiO) Randomized Controlled Trial. Nutrients. 2019 Oct 22;11(10):2543. doi: 10.3390/nu11102543.
- Papakonstantinou E, Triantafillidou D, Panagiotakos DB, Koutsovasilis A, Saliaris M, Manolis A, Melidonis A, Zampelas A. A high-protein low-fat diet is more effective in improving blood pressure and triglycerides in calorie-restricted obese individuals with newly diagnosed type 2 diabetes. Eur J Clin Nutr. 2010 Jun;64(6):595-602. doi: 10.1038/ejcn.2010.29. Epub 2010 Mar 10.
- Sun P, Huang L, Shuai P, Wan Z, Liu Y, Xue J, Liu Y. Effect of a High Protein, Low Glycemic Index Dietary Intervention on Metabolic Dysfunction-Associated Fatty Liver Disease: A Randomized Controlled Trial. Front Nutr. 2022 Apr 27;9:863834. doi: 10.3389/fnut.2022.863834. eCollection 2022.
- Xu C, Markova M, Seebeck N, Loft A, Hornemann S, Gantert T, Kabisch S, Herz K, Loske J, Ost M, Coleman V, Klauschen F, Rosenthal A, Lange V, Machann J, Klaus S, Grune T, Herzig S, Pivovarova-Ramich O, Pfeiffer AFH. High-protein diet more effectively reduces hepatic fat than low-protein diet despite lower autophagy and FGF21 levels. Liver Int. 2020 Dec;40(12):2982-2997. doi: 10.1111/liv.14596. Epub 2020 Jul 21.
- Skytte MJ, Samkani A, Petersen AD, Thomsen MN, Astrup A, Chabanova E, Frystyk J, Holst JJ, Thomsen HS, Madsbad S, Larsen TM, Haugaard SB, Krarup T. A carbohydrate-reduced high-protein diet improves HbA1c and liver fat content in weight stable participants with type 2 diabetes: a randomised controlled trial. Diabetologia. 2019 Nov;62(11):2066-2078. doi: 10.1007/s00125-019-4956-4. Epub 2019 Jul 23.
- Markova M, Pivovarova O, Hornemann S, Sucher S, Frahnow T, Wegner K, Machann J, Petzke KJ, Hierholzer J, Lichtinghagen R, Herder C, Carstensen-Kirberg M, Roden M, Rudovich N, Klaus S, Thomann R, Schneeweiss R, Rohn S, Pfeiffer AF. Isocaloric Diets High in Animal or Plant Protein Reduce Liver Fat and Inflammation in Individuals With Type 2 Diabetes. Gastroenterology. 2017 Feb;152(3):571-585.e8. doi: 10.1053/j.gastro.2016.10.007. Epub 2016 Oct 17.
- Mackowiak B, Fu Y, Maccioni L, Gao B. Alcohol-associated liver disease. J Clin Invest. 2024 Feb 1;134(3):e176345. doi: 10.1172/JCI176345.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- HP-AFLD-RCT
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em high protein diet
-
Charite University, Berlin, GermanyConcluído
-
Vastra Gotaland RegionGöteborg UniversityInscrevendo-se por convite
-
George Washington UniversityConcluídoAmamentaçãoEstados Unidos
-
Mondelēz International, Inc.KGK Science Inc.ConcluídoExcesso de pesoEstados Unidos
-
University of St.GallenInsel Gruppe AG, University Hospital BernRecrutamentoHábitos de dieta | Dieta Saudável | Hábitos alimentares | Nutrição, SaudávelSuíça
-
The University of Texas Health Science Center at...ConcluídoTranstorno de Déficit de Atenção com HiperatividadeEstados Unidos
-
H. Lee Moffitt Cancer Center and Research InstituteNestle Health ScienceRetiradoNSCLC | Câncer de Pulmão de Células Não Pequenas | Câncer de Pulmão de Células Não Pequenas | NSCLC Estágio IIIB | Câncer de Pulmão de Células Não Pequenas Estágio IIIB | NSCLC, estágio IIIA | Câncer de Pulmão de Células Não Pequenas Estágio ⅢAEstados Unidos
-
Institute of Mother and Child, Warsaw, PolandMinistry of Health, PolandConcluídoPressão arterial | Excesso de peso, Infância | Prevenção da ObesidadePolônia
-
University of HullConcluído
-
B.Braun Avitum AGWinicker Norimed GmbHConcluídoInsuficiência Renal Crônica | Insuficiência Renal | Doença Renal em Estágio Terminal | Insuficiência Renal CrônicaRepública Checa